Trevena Inc

Trevena Inc. Announces $4 Million Concurrent Private Placement and Warrant Exercise

Retrieved on: 
Wednesday, December 27, 2023
Regulation D, Sale, Form, Act, Loan agreement, Trevena Inc, CNS, Patient, Central nervous system, The Act, Tranche, Exercise, Security (finance)

The shares of common stock issuable upon exercise of the existing warrants are registered pursuant to an effective registration statement on Form S-3 (File No.

Key Points: 
  • The shares of common stock issuable upon exercise of the existing warrants are registered pursuant to an effective registration statement on Form S-3 (File No.
  • 333-251006), filed with the U.S. Securities Exchange (“SEC”) on November 27, 2020 and declared effective on December 4, 2020.
  • H.C. Wainwright & Co. is acting as the exclusive placement agent for the offerings.
  • The aggregate gross proceeds to the Company from the offerings are expected to be approximately $4 million, before deducting placement agent fees and other offering expenses.

Trevena Awarded OLINVYK Agreement with Premier, Inc.

Retrieved on: 
Monday, December 4, 2023
Premier, Central nervous system, Patient, Trevena Inc, Hospital, CNS

CHESTERBROOK, Pa., Dec. 04, 2023 (GLOBE NEWSWIRE) -- Trevena Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, has been awarded a national group purchasing agreement for OLINVYK with Premier, Inc.

Key Points: 
  • CHESTERBROOK, Pa., Dec. 04, 2023 (GLOBE NEWSWIRE) -- Trevena Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, has been awarded a national group purchasing agreement for OLINVYK with Premier, Inc.
  • Effective December 1, 2023, the new agreement allows Premier members, at their discretion, to take advantage of special pricing and terms pre-negotiated by Premier for OLINVYK.
  • Premier is a leading healthcare improvement company, uniting an alliance of approximately 4,350 U.S. hospitals and 300,000 other providers to transform healthcare.
  • With integrated data and analytics, collaboratives, supply chain solutions, consulting and other services, Premier enables better care and outcomes at a lower cost.

Trevena Announces Receipt of $15 Million Non-Dilutive Tranche and Provides General Business Update

Retrieved on: 
Wednesday, September 6, 2023
Real-World Evidence, Seizure, ASA, Abstract (summary), Abstract, Cleveland Clinic, Central nervous system, Doctor of Pharmacy, Trevena Inc, Use, Senior, Delirium, Vomiting, TMS, Trevena, American Society of Anesthesiologists, Spasm, Research, CNS, Sale, Conference call, Patient, Webcast, Pain, Society, Conference, Receptor, Rare-earth element, Cryptocurrency, Pharmaceutical industry

This tranche of funding was triggered by the first commercial sale of OLINVYK in China by Jiangsu Nhwa, the Company’s licensee in China.

Key Points: 
  • This tranche of funding was triggered by the first commercial sale of OLINVYK in China by Jiangsu Nhwa, the Company’s licensee in China.
  • The $15 million tranche is in addition to the $28.1 million of cash and cash equivalents the Company previously reported as of June 30, 2023.
  • As part of the R-Bridge Financing, Trevena may receive an additional $10 million upon achievement of either a commercial or financing milestone.
  • Trevena expects to report new respiratory data from the study using continuous respiratory monitoring in 3Q 2023.

Trevena Announces Receipt of Milestone Payment From Partner in China Jiangsu Nhwa Pharmaceutical

Retrieved on: 
Wednesday, May 31, 2023
Trevena, Central nervous system, Campbell R. Bridges, Trevena Inc, Patient, CNS, Sale, Pharmaceutical industry

CHESTERBROOK, Pa., May 31, 2023 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced that it has received a $3 million milestone payment from its partner in China for the Chinese approval of OLINVYK. Jiangsu Nhwa Pharmaceutical Co. Ltd. (Nhwa) holds an exclusive license agreement to develop, manufacture, and commercialize OLINVYK in China.

Key Points: 
  • Jiangsu Nhwa Pharmaceutical Co. Ltd. (Nhwa) holds an exclusive license agreement to develop, manufacture, and commercialize OLINVYK in China.
  • "We look forward to continuing to work closely to support Nhwa in their commercial efforts.
  • They have already begun commercial efforts in China and we are excited to see OLINVYK made available in such an important market,” said Carrie Bourdow, President and CEO of Trevena, Inc.
  • The Company also reaffirmed the expected receipt of $15 million in non-dilutive financing from R-Bridge upon first commercial sale of OLINVYK in China, which Nhwa believes will occur in 3Q 3023.

Trevena Regains Compliance with Nasdaq Listing Requirements

Retrieved on: 
Tuesday, November 29, 2022
Trevena Inc, Epilepsy, Trevena, Patient, Pain, Central nervous system disease, Maintenance, Nobel Prize, Central nervous system, CNS, Letter, Research, TRV734, Migraine, Health insurance, Pharmaceutical industry

CHESTERBROOK, Pa., Nov. 29, 2022 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced that it has received notice from the Listing Qualifications Department of the Nasdaq Stock Market LLC (Nasdaq) by letter dated November 28, 2022 informing Trevena that it has regained compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2).

Key Points: 
  • CHESTERBROOK, Pa., Nov. 29, 2022 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced that it has received notice from the Listing Qualifications Department of the Nasdaq Stock Market LLC (Nasdaq) by letter dated November 28, 2022 informing Trevena that it has regained compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2).
  • The Company maintained a minimum closing bid price of $1.00 or more for at least 10 consecutive trading days and, as a result of regaining compliance, its common stock will continue to be listed on the Nasdaq Capital Market.
  • Trevena, Inc. is a biopharmaceutical company focused on the development and commercialization of innovative medicines for patients with CNS disorders.
  • The Company has one approved product in the United States, OLINVYK (oliceridine) injection, indicated in adults for the management of acute pain severe enough to require an intravenous opioid analgesic and for whom alternative treatments are inadequate.

Trevena, Inc. Announces $8.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Retrieved on: 
Wednesday, November 16, 2022
Trevena Inc, COVID-19, Epilepsy, Trevena, Form S-3, 3rd Floor, Patient, Pain, Central nervous system disease, Prospectus, Maintenance, Nobel Prize, Central nervous system, CNS, Sale, Risk, Research, Form, Park Avenue, TRV734, Migraine, FDA, Security (finance), Pharmaceutical industry

The closing of the offering is expected to occur on or about November 18, 2022, subject to the satisfaction of customary closing conditions.

Key Points: 
  • The closing of the offering is expected to occur on or about November 18, 2022, subject to the satisfaction of customary closing conditions.
  • H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering.
  • Total gross proceeds from the offering, before deducting the placement agent's fees and other offering expenses, is expected to be approximately $8.0 million.
  • The offering will be made only by means of a prospectus supplement that forms a part of the registration statement.

Marinus Pharmaceuticals Appoints CEO Scott Braunstein, M.D., as Chairman of the Board

Retrieved on: 
Thursday, November 17, 2022
Biotechnology, Health, Science, Pharmaceutical, Research, FDA, Medication, Clinical trial, Summit Medical Group, Brain, Epilepsy, Ganaxolone, J. P. Morgan, CDKL5, Prescription, Albert Einstein College of Medicine, Annual report, Prodrug, Rachel Haurwitz, Security (finance), Marinus, Form 10-K, FTSE Global Equity Index Series, IV, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Columbia University Irving Medical Center, Therapy, Trevena Inc, Growth, COVID-19, CV, Seizure, GABAA, Risk, EMA, Food, Patient, Management, Pharmaceutical industry

Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, announced that the Board of Directors has appointed Chief Executive Officer (CEO) and Board Director, Scott Braunstein, M.D., as Chairman of the Board.

Key Points: 
  • Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, announced that the Board of Directors has appointed Chief Executive Officer (CEO) and Board Director, Scott Braunstein, M.D., as Chairman of the Board.
  • Newly appointed Lead Independent Board Director for Marinus, Tim M. Mayleben, said, "We are thrilled with the Companys transformation over the last few years under Scotts management.
  • We look forward to complementing the skills and expertise of the Board with new members to support efforts to scale Marinus.
  • I look forward to working with Tim as we evolve and enhance the Marinus Board with additional capabilities, said Chairman and CEO, Scott Braunstein.

Trevena Announces Reverse Stock Split

Retrieved on: 
Wednesday, November 9, 2022
Transfer, Director, GLOBE, Trevena Inc, Nasdaq, Central nervous system disease, Research, Epilepsy, Board, Trevena, CUSIP, Nobel Prize, Exercise, Pain, Migraine, Compliance, Time, Company, Maintenance, Patient, TRV734, Central nervous system, CNS, Pharmaceutical industry, Security (finance), Amendment

The reverse stock split is intended to enable Trevena to regain compliance with the$1.00minimum bid price required for continued listing on the Nasdaq Capital Market.The new CUSIP number for Trevenas common stock following the reverse stock split will be 89532E 208.

Key Points: 
  • The reverse stock split is intended to enable Trevena to regain compliance with the$1.00minimum bid price required for continued listing on the Nasdaq Capital Market.The new CUSIP number for Trevenas common stock following the reverse stock split will be 89532E 208.
  • The reverse stock split will affect all shares of the Companys common stock outstanding immediately prior to the effective time of the reverse stock split, as well as the number of shares of common stock available for issuance under the Companys equity incentive plans.
  • In addition, the reverse stock split will effect a reduction in the number of shares of common stock issuable upon the exercise of stock options and warrants outstanding immediately prior to the effectiveness of the reverse stock split with a corresponding increase in exercise price per share.
  • Stockholders who would otherwise be entitled to receive fractional shares as a result of the reverse stock split will be entitled to a cash payment in lieu thereof at a price equal to the fraction to which the stockholder would otherwise be entitled multiplied by the closing trading price per share of the common stock (as adjusted for the reverse stock split) as reported on The Nasdaq Capital Market on November 9, 2022.

Trevena Announces Completion of Phase 1 Study for TRV045, Novel S1P Receptor Modulator

Retrieved on: 
Wednesday, November 9, 2022
Well, Extremities, Trevena Inc, Research, Chemokine, Trevena, Brain, Company, Chemotherapy-induced peripheral neuropathy, Human, Cell, Absorption, Security (finance), Blood pressure, Plasma, Heart rate, Seizure, SEC, Pain, Hyperalgesia, U.S. Securities and Exchange Commission, Inflammation, Private Securities Litigation Reform Act, Patient, CEO, COVID-19, Risk, PK, DNP, Opioid use disorder, Diabetes, National, Conditional sentence, Cytokine, CDC, Half-life, Astrocyte, Acute respiratory distress syndrome, Wireless ambulatory ECG, Maintenance, Diabetic neuropathy, Hypoesthesia, Central nervous system, Allodynia, Food, CNS, FDA, GLOBE, Nature, Headache, Central nervous system disease, Epilepsy, Nobel Prize, Migraine, Safety, Lymphocytopenia, Neuropathic pain, TRV734, Pharmaceutical industry, Vaccine, Dietary supplement, S1P1

CHESTERBROOK, Pa., Nov. 09, 2022 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced positive clinical data for TRV045, its selective sphingosine-1-phosphate subtype 1 (S1P1) receptor modulator. The 3-part randomized, double-blind, placebo-controlled Phase 1 study evaluated safety, tolerability and PK in healthy volunteers. TRV045 is being developed as a potential treatment for diabetic neuropathic pain (DNP). Through a collaboration with the National Institutes of Health, the Company is also exploring TRV045 as a potential treatment for epilepsy.

Key Points: 
  • Were pleased to report positive Phase 1 data on our novel S1P1 receptor modulator, TRV045, which are consistent with its distinct mechanism of action, said Carrie Bourdow, President and CEO of Trevena.
  • This study was a three-part study design, examining the PK profile, safety and tolerability of orally administered TRV045 in healthy volunteers.
  • Part 1 Single Ascending Dose: This study phase investigated the PK profile, safety and tolerability of single ascending doses of TRV045 or placebo.
  • Part 2 Food Effect: This study phase investigated the PK profile, safety and tolerability of TRV045 administered with a high-fat meal in 3 study cohorts.

Trevena to Release Third Quarter 2022 Financial Results on November 9, 2022

Retrieved on: 
Monday, November 7, 2022
TRV734, Pain, Epilepsy, Company, Migraine, Research, CNS, Webcast, Maintenance, Central nervous system disease, Trevena Inc, Patient, Nobel Prize, Broadcasting, Pharmaceutical industry

The conference call will be webcast live from the Companys website and will be available via the following links:

Key Points: 
  • The conference call will be webcast live from the Companys website and will be available via the following links:
    The webcast should be accessed 15 minutes prior to the conference call start time.
  • A replay of the webcast will be available following the conclusion of the live broadcast and will be accessible on the Companys website.
  • Trevena, Inc. is a biopharmaceutical company focused on the development and commercialization of innovative medicines for patients with CNS disorders.
  • The Company has one approved product in the United States, OLINVYK (oliceridine) injection, indicated in adults for the management of acute pain severe enough to require an intravenous opioid analgesic and for whom alternative treatments are inadequate.